C4 Therapeutics, Inc.

CCCC

Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
SEC CIK: 0001662579

SEC filings (opens in a new tab)

No open-market purchases or sales by C4 Therapeutics, Inc. insiders were filed in the last 90 days; 147 institutions reported holding it in 13F filings for Q2 2026, worth $547.6M in total; no superinvestor holds it.

Q1 2026 vs. Q4 2025

How the institutions holding C4 Therapeutics, Inc. changed between Q4 2025 and Q1 2026.

All holders in Q1 2026 All holders in Q4 2025

13F holders of CCCC: Q4 2025 compared with Q1 2026
Measure	Q4 2025	Of which not filed for Q1 2026	Q1 2026	Change
Holders	101	1	123	+23
Shares	79.8M	4.38M	84.5M	+9.04M (+12.0%)
Value	$152.5M	$8.37M	$221.3M	+$77.2M (+53.6%)

1 institution that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so the changes leave them out.

New holders (34)

Institutions that held C4 Therapeutics, Inc. at the end of Q1 2026 but not at the end of Q4 2025.

Institutions new to CCCC in Q1 2026
Institution	Shares	Value	% of portfolio
Vanguard Capital Management LLC	3,861,852	$10.2M	0.00%
Squadron Capital Management LLC	2,250,000	$5.92M	2.37%
Congress Asset Management Co	830,624	$2.18M	0.02%
Vanguard Fiduciary Trust Co	484,131	$1.27M	0.00%
StemPoint Capital LP	453,236	$1.19M	0.23%
Platinum Investment Management Ltd	384,766	$1.01M	0.26%
Jacobs Levy Equity Management, Inc	264,620	$696.0K	0.00%
Toronto Dominion Bank	174,663	$459.4K	0.00%
HRT Financial LP	162,930	$428.0K	0.00%
Verdad Advisers, LP	109,407	$287.7K	0.32%
Brevan Howard Capital Management LP	92,647	$243.7K	0.00%
Panagora Asset Management Inc	86,760	$228.2K	0.00%
Axq Capital, LP	86,278	$226.9K	0.03%
Seven Fleet Capital Management LP	57,076	$150.1K	0.05%
Readystate Asset Management LP	49,586	$130.4K	0.01%
ADAR1 Capital Management, LLC	43,000	$113.1K	0.01%
Diametric Capital, LP	34,594	$91.0K	0.02%
Vanguard Global Advisers, LLC	33,832	$89.0K	0.00%
Prelude Capital Management, LLC	30,957	$81.4K	0.01%
SEI Investments Co	25,134	$66.1K	0.00%
Winton Group Ltd	24,700	$65.0K	0.00%
Schonfeld Strategic Advisors LLC	23,944	$63.0K	0.00%
Dauntless Investment Group, LLC	15,000	$39.5K	0.11%
CTC Alternative Strategies, Ltd.	10,792	$28.4K	0.06%
SummitTX Capital, L.P.	10,466	$27.5K	0.00%
Two Sigma Securities, LLC	10,203	$26.8K	0.00%
Owl Creek Wealth Partners LLC	2,140	$5.63K	0.00%
Federated Hermes, Inc.	1,878	$4.94K	0.00%
Caitong International Asset Management Co., Ltd	592	$1.56K	0.00%
Fortitude Family Office, LLC	435	$1.14K	0.00%
Jones Financial Companies LLLP	278	$670	0.00%
Harbour Investments, Inc.	90	$237	0.00%
Advisory Services Network, LLC	74	$195	0.00%
Hantz Financial Services, Inc.	3	$0	0.00%

Sold out (11)

Institutions that held C4 Therapeutics, Inc. at the end of Q4 2025 and filed for Q1 2026 without it.

Institutions that sold out of CCCC in Q1 2026
Institution	Shares, Q4 2025	Value, Q4 2025
Two Sigma Advisers, LP	1,068,200	$2.04M
ArrowMark Colorado Holdings LLC	204,505	$390.6K
Susquehanna Fundamental Investments, LLC	67,617	$129.1K
Group One Trading, L.P.	38,994	$74.5K
Lighthouse Investment Partners, LLC	33,660	$64.3K
Simplex Trading, LLC	30,658	$58.6K
Engineers Gate Manager LP	24,416	$46.6K
Virtu Financial LLC	20,655	$39.0K
Delta Investment Management, LLC	20,000	$38.2K
R Squared Ltd	13,674	$26.1K
Optima Capital LLC	226	$432

Not filed for Q1 2026 yet (1)

Institutions that held C4 Therapeutics, Inc. at the end of Q4 2025 and haven't filed a 13F for Q1 2026. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding CCCC in Q4 2025 that haven't filed for Q1 2026
Institution	Shares, Q4 2025	Value, Q4 2025
Vanguard Group Inc	4,379,815	$8.37M